Navigation Links
Vermillion to Present at the 2012 Gateway Conference on September 6
Date:8/28/2012

AUSTIN, Texas, Aug. 28, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has been invited to present at the 2012 Gateway Conference being held on September 6 at the W San Francisco Hotel.

Vermillion management is scheduled to present at 11:00 a.m. Pacific time, with one-on-one meetings held throughout the day. As the first FDA-cleared blood test for pre-surgical cancer diagnosis of ovarian tumors by using a unique multi-biomarker approach, management will discuss the company's progress in making OVA1® the standard of care in the diagnosis of ovarian cancer.

To schedule a one-on-one meeting, visit www.gateway-conference.com and click on the Register/Login tab. You may also email your request to schedule@gateway-conference.com or call Ron Both at (949) 574-3860.

About the Gateway Conference
Gateway Conference is designed to provide a unique gateway between influential members of the investment community and a select group of compelling publicly-traded companies. Portfolio managers, research analysts and brokers from buy-side and sell-side institutions will have the opportunity to learn about more than 50 emerging growth companies across a broad range of industries, from technology, business services and digital media, to clean-tech, consumer/retail, life sciences and natural resources.  For more information, go to www.gateway-conference.com.

The invitation-only conference is hosted by Liolios Group, one of the nation's top investor relations agencies, and sponsored by leading firms that service the financial community. For more information about Liolios Group, visit www.liolios.com.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at www.vermillion.com.

Investor Relations Contact:
Liolios Group
Scott Liolios or Ron Both
Tel 949-574-3860
vrml@liolios.com


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Vermillion Reports Second Quarter 2012 Results
6. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
7. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
8. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
9. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
10. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
(Date:4/18/2017)... -- Spero Therapeutics, LLC, a biopharmaceutical company founded to develop ... present preclinical data supporting the use of SPR741 combination ... infections at the 27th European Congress of Clinical Microbiology ... Vienna, Austria . ... "Our ongoing preclinical research helps ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... , ... Ecommerce sales have grown every year since the 1990’s, with 2016 ... consequences of rapid innovation and growth are often neglected in the name of progress. ... and individual’s job to give something back to the planet that provides the resources ...
(Date:4/22/2017)... Capistrano (PRWEB) , ... April 22, 2017 , ... The San Juan Capistrano summer ... released a parenting report outlining the need for summer camps to provide physical activities for ... Importance of Physical Activity In Summer Camps , With an increase in specialty camps that ...
(Date:4/21/2017)... MA (PRWEB) , ... April 21, 2017 , ... ... University professor Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. ... the relative proportion of young people involved in violence in the United States. ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, an insurance ... throughout the greater Pittsburgh metropolitan region, is joining forces with the local chapter ... differently-abled children. , Variety the Children’s Charity is a national organization dedicated to ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... announced it’s been named Agency of Record (AOR) for Theravent, Inc. , ... eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand ...
Breaking Medicine News(10 mins):